Biogen reports better-than-expected first-quarter earnings and says the pandemic brings "unanticipated and potentially unquantifiable risks to our business" near term.

Jim Cramer says fear is widespread, and it's impossible to call the bottom. But he recalls the wisdom of Warren Buffett.

Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.

Here's what you need to know now for Wednesday, Feb. 14.

Jim Cramer is bullish on Delta Air Lines, BioTelemetry, TransUnion, Amgen and Littelfuse.

Jim Cramer says there's a case to be made for underpricing, even in this market.

People who are traveling by air are about to see a change in recent trends.

Beverage giant is rolling out a new taste in its efforts to attract and keep a key demographic.

You can find savings on everything from EVs to solar panels in the Inflation Reduction Act.